Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of LNK01001 in active ankylosing spondylitis
CTR20233855Phase 3Active
- Sponsor
- Lynk Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zemprocitinib in ankylosing spondylitis (AS), sponsored by Lynk Pharmaceuticals. Started Aug 2025; status: active.
02
Drugs
zemprocitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20233855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233855.